CTSO vs ICUI vs BDX vs NVCR vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -6. 4% for ICU Medical, Inc. (ICUI). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate ICU Medical, Inc. (ICUI) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus ICU Medical, Inc. at 4186. 1x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -92. 8% for Cytosorbents Corporation (CTSO). Over 10 years, the gap is even starker: BSX returned +155. 5% versus CTSO's -86. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 541% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 2% for Cytosorbents Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -6. 4% for ICU Medical, Inc. (ICUI). On earnings-per-share growth, the picture is similar: ICU Medical, Inc. grew EPS 100. 6% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -58. 2% for Cytosorbents Corporation — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -47. 2% for CTSO. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12.

3x forward P/E versus 16. 7x for Boston Scientific Corporation — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, BDX (2.

7% yield) pays a dividend. CTSO, ICUI, NVCR, BSX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +80. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTSO is a small-cap quality compounder stock; ICUI is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; BSX is a mid-cap high-growth stock. BDX pays a dividend while CTSO, ICUI, NVCR, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.